arrow
M

Michael A. Pulsipher

baylor college medical hospital
H指数:77
被引数:2.5万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

IMPACT (Immune Monitoring and Phenotype Assessment of Clinical Trajectory) for Patients With Inborn Errors of Immunity From the Primary Immune Deficiency Treatment Consortium (PIDTC)

免疫监测和表型评估对临床轨迹的影响(IMPACT),用于原发性免疫缺陷治疗联盟(PIDTC)中免疫先天性错误疾病患者

2026-08-010
PRE
CD19 CAR T-cell outcomes in relapsed/refractory extramedullary B-ALL: a multi-site, retrospective cohort review

CD19 CAR T细胞在复发/难治性髓外B-ALL中的疗效:一项多中心、回顾性队列研究

2026-02-190
OAAI
Harmonization on defining B-cell recovery post CD19-CAR T-cell therapy in B-cell acute lymphoblastic leukemia: An international consensus statement

关于CD19-CAR T细胞疗法后B细胞恢复定义的标准化:一项国际共识声明

2025-11-120
OAAI
Opportunities and Challenges with CAR T-cell Treatment of Children and Young Adults with B-Cell Acute Lymphoblastic Leukemia: Review and Recommendations from the Westhafen Intercontinental Group

CAR T细胞治疗儿童和年轻成人B细胞急性淋巴细胞白血病的机遇与挑战:Westhafen Intercontinental Group的综述与建议

2025-10-300
OAAI
Distinct Biological Subtypes of Chronic GvHD after Pediatric Hematopoietic Cell Transplantation

儿童造血细胞移植后慢性移植物抗宿主病的不同生物学亚型

Blood
IF23.1
2025-10-100
PRE
Umbilical Cord Blood Transplantation Provides an Alternative for Patients with Chronic Granulomatous Disease Lacking HLA-Matched Donors: a PIDTC Report

脐带血移植为缺乏HLA匹配供体的慢性肉芽肿病患者提供了替代方案:一份PIDTC报告

2025-10-020
PRE
Identification of Distinct Subtypes in Immune Tolerance after Hematopoietic Cell Transplantation Using the Prospective ABLE1.0 Pediatric Study Cohort

使用前瞻性ABLE1.0儿科研究队列,识别造血细胞移植后免疫耐受中的不同亚型

2025-09-290
OAAI
Integrating pulmonary and systemic transcriptomes to characterize lung injury after pediatric hematopoietic stem cell transplant

整合肺和系统性转录组以表征儿童造血干细胞移植后的肺损伤

2025-09-090
OA
Harmonized Immune Recovery Monitoring after HCT: Evidence & Practical Guidance from the Westhafen Intercontinental Group

异基因造血干细胞移植后免疫重建监测的标准化:Westhafen Intercontinental Group的证据与实践指南

2025-09-050
OAAI
Real-world data for tisagenlecleucel in patients with R/R B-ALL: subgroup analyses from the CIBMTR registry

tisagenlecleucel 在复发/难治性B-ALL患者中的真实世界数据:来自CIBMTR登记研究的亚组分析

2025-06-260
OAAI
Evaluation of in vivo CAR transgene levels in tisagenlecleucel-treated patients with relapsed/refractory B-ALL and DLBCL

评估接受tisagenlecleucel治疗的复发/难治性B-ALL和DLBCL患者体内CAR转座子水平的评价

2025-06-260
OAAI
High Melphalan Exposure Increases the Risk of Graft-Versus-Host Disease in Pediatric Patients Undergoing Alpha-Beta T-Cell Depleted Haploidentical Transplantation

高美法仑暴露增加接受αβ-T细胞去除半相合移植的儿科患者发生移植物抗宿主病的风险

2025-06-010
PRE
Outcomes of PLAT-02 and PLAT-03: evaluating CD19 CAR T-cell therapy and CD19-expressing T-APC support in pediatric B-ALL

PLAT-02和PLAT-03的研究结果:评估CD19 CAR T细胞疗法及CD19表达T-APC支持在儿童B-ALL中的应用

Blood
IF23.1
2025-04-170
PRE
The Adverse Event Landscape of Stem Cell Transplant: Evidence for AGVHD Driving Early Transplant Associated Toxicities
2025-02-010
PRE
Allogeneic Hematopoietic Cell Transplantation for the Treatment of Severe Aplastic Anemia: Evidence-Based Guidelines From the American Society for Transplantation and Cellular Therapy

异基因造血干细胞移植治疗重型再生障碍性贫血: 美国移植与细胞治疗学会循证指南

2024-12-011
OAAI
Effect of rabbit ATG PK on outcomes after TCR-αβ/CD19-depleted pediatric haploidentical HCT for hematologic malignancy
2024-11-271
OAAI
A Validated Risk Strati fi cation That Incorporates MAGIC Biomarkers Predicts Long-Term Outcomes in Pediatric Patients with Acute GVHD

包含神奇生物标志物的经过验证的风险分层可预测急性GVHD患儿的长期预后

2024-06-012
OAAI